You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CIK

Showing 1 - 25 of 131
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Trial in Chongqing (CIK combined with chemo group, CIK combined immunotherapy group, CIK combined targeted

Recruiting
  • Colorectal Cancer
  • CIK combined with chemotherapy group
  • +3 more
  • Chongqing, Chongqing, China
    Southwest Hospital, Army Medical University (Third Military Medi
Jan 6, 2023

Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor Trial in Petaling Jaya (Dendritic cell + Cytokine-induced killer cell

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Advanced Solid Tumor
  • Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy
  • Tegafur Only Product
  • Petaling Jaya, Kuala Lumpur, Malaysia
    Clinical Oncology Department, Ummc
Jul 12, 2023

Solid Tumor Trial in Yantai (DC-CIK combined with Chemotherapy, Chemotherapy)

Recruiting
  • Solid Tumor
  • Yantai, Shandong, China
    Yantai Yuhuangding Hospital
Feb 7, 2022

Relapsed Hematologic Malignancy Trial in Bergamo (donor-derived CIK cells)

Recruiting
  • Relapsed Hematologic Malignancy
  • donor-derived CIK cells
  • Bergamo, Italy
    A O Papa Giovanni XXIII
Dec 22, 2021

Sarcoma Trial in Turin (Autologous CIK)

Recruiting
  • Sarcoma
  • Autologous CIK
  • Turin, Italy
    AOU Città della Salute e della Scienza di Torino - Presidio Infa
Aug 11, 2022

Advanced Liver Cancers Trial (DC-CIK)

Not yet recruiting
  • Advanced Liver Cancers
  • DC-CIK
  • (no location specified)
Nov 11, 2022

MDS, Acute Leukemia Trial in Germany (CIK-Cells)

Active, not recruiting
  • Myelodysplastic Syndromes
  • Acute Leukemia
  • Heidelberg, Baden-Württemberg, Germany
  • +4 more
Mar 31, 2022

B-cell NHL, CLL Trial (CARCIK-CD19)

Not yet recruiting
  • B-cell NHL
  • CLL
  • CARCIK-CD19
  • (no location specified)
May 19, 2023

Advanced Liver Cancer Trial in Beijing (Activated CIK, CIK)

Recruiting
  • Advanced Liver Cancer
  • Activated CIK
  • CIK
  • Beijing, Beijing, China
    302 Military Hospital of China
Jan 27, 2021

Advanced Solid Tumor Trial in Taoyuan (Neoantigen-expanded cell therapy.)

Recruiting
  • Advanced Solid Tumor
  • Neoantigen-expanded cell therapy.
  • Taoyuan, Taiwan
    Chang Gung Memorial Hospital, Linkou
Aug 18, 2021

Sarcoma Trial in Torino (Autologous CIK Dose level 1, Autologous CIK Dose level 2, Autologous CIK Dose level 3)

Withdrawn
  • Sarcoma
  • Autologous CIK Dose level 1
  • +3 more
  • Torino, Italy
    Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoem
Dec 18, 2020

Pleural Effusion, Malignant Trial (IFN-? and CIK cells, Tcm cells or CAR T cells)

Not yet recruiting
  • Pleural Effusion, Malignant
  • IFN-γ and CIK cells, Tcm cells or CAR T cells
  • (no location specified)
Mar 16, 2022

NSCLC Metastatic, First-line Treatment Trial in Tianjin (CIK cell injection, Sintilimab Injection, Pemetrexed)

Not yet recruiting
  • Non-small Cell Lung Cancer Metastatic
  • First-line Treatment
  • CIK cell injection
  • +4 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Apr 6, 2021

Advanced Breast Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer,

Withdrawn
  • Advanced Breast Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Colorectal Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer,

Withdrawn
  • Advanced Colorectal Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating colorectal cancer
  • Cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Pancreatic Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer,

Withdrawn
  • Advanced Pancreatic Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Pancreatic Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Lung Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer, Cryotherapy)

Withdrawn
  • Advanced Lung Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Lung cancer
  • Cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Gastric Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer,

Withdrawn
  • Advanced Gastric Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Gastric cancer
  • Cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Kidney Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer,

Withdrawn
  • Advanced Kidney Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
    Institutional Review Board of Guangzhou Fuda Cancer Hospital
Oct 13, 2020

Advanced Liver Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer, cryotherapy)

Withdrawn
  • Advanced Liver Cancer
  • Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Liver Cancer
  • cryotherapy
  • Guangzhou, Guangdong, China
  • +1 more
Oct 13, 2020

Liver Cancer, Kidney Cancer, Nasopharyngeal Cancer Trial in Guangzhou (CELL)

Recruiting
  • Liver Cancer
  • +5 more
  • CELL
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Jul 14, 2020

Colon Cancer Stage IV Trial in Tehran (Cytokine-induced killer cell, Chemotherapy AND/OR Radiation Therapy)

Recruiting
  • Colon Cancer Stage IV
  • Cytokine-induced killer cell
  • Chemotherapy AND/OR Radiation Therapy
  • Tehran, Iran, Islamic Republic of
    Gene Therapy Research Center, Digestive Disease Research Institu
Mar 11, 2021

Malignant Tumor Trial in Shenzhen (Decitabine, DC-CIK)

Unknown status
  • Malignant Neoplasm
  • Shenzhen, China
    Shenzhen university general hospital
Feb 28, 2020

Lung Adenocarcinoma Trial in ZhengZhou (CIK, chemo)

Terminated
  • Lung Adenocarcinoma
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
May 10, 2021

Esophageal Carcinoma Trial in Beijing (concurrent chemoradiotherapy plus DC-CIK immunotherapy, Concurrent chemoradiation only)

Unknown status
  • Esophageal Carcinoma
  • concurrent chemoradiotherapy plus DC-CIK immunotherapy
  • Concurrent chemoradiation only
  • Beijing, Beijing, China
    Capital Medical University Cancer Center
Jan 2, 2020